ea0084op-03-14 | Oral Session 3: Advanced Thyroid Cancer | ETA2022
W Bowles Daniel
, Bazhenova Lyudmila
, Hescot Segolene
, Folprecht Gunnar
, Daga Haruko
, Massarelli Erminia
, P Conley Anthony
, Lamartina Livia
, Lin Jessica
, Ahn Eugene
, Osborne Stuart
, Heinzmann Sebastian
, Carrizosa Daniel
Objectives: NTRK gene fusions are oncogenic drivers in many solid tumours, including thyroid cancers. In the phase 2 study STARTRK-2 (NCT02568267), entrectinib (a CNS-active tropomyosin receptor kinase [TRK] inhibitor) demonstrated efficacy in patients with NTRK-fp thyroid cancer (objective response rate [ORR]: 40%; clinical cut-off: 31 Oct 2018; n=5). We report updated data from a larger cohort with longer follow-up.Methods: A...